pargyline has been researched along with Parkinsonian Disorders in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pretreatment with pargyline attenuated the MPTP-induced clinical signs, MRI and MRS changes, and the histopathological and immunoreactivity alterations." | 1.32 | Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. ( Hadjiconstantinou, M; Neff, NH; Podell, M; Smith, MA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Podell, M | 1 |
| Hadjiconstantinou, M | 1 |
| Smith, MA | 1 |
| Neff, NH | 1 |
| Andringa, G | 1 |
| Cools, AR | 1 |
2 other studies available for pargyline and Parkinsonian Disorders
| Article | Year |
|---|---|
Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Brain; Cats; Choline; Corpus S | 2003 |
The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey.
Topics: Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Macaca mulatta; Male; Neur | 2000 |